Mecapegfilgrastim is named as an intervention in 5 current clinical trials in our China register. 3 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Fudan University (1). The most-studied condition is Triple-negative Breast Cancer.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Reverse Triple Negative Immune Resistant Breast Cancer
NCT05076682 · ClinicalTrials.gov ↗ · Triple-negative Breast Cancer
|
Phase 2 | Recruiting | Fudan University | China |
|
Clinical Study of Thiopegfilgrastim for Preventing Bone Marrow Suppression in Thoracic Tumor Chemoradiotherapy
NCT07205536 · ClinicalTrials.gov ↗ · Myelosuppression, Thoracic Neoplasms, Chemoradiotherapy
|
Phase 2 | Recruiting | Affiliated Hospital of Nantong University | China |
|
Real-world Study on the Prevention of Neutropenia After Tumor Treatment With Mecapegfilgrastim Injection
NCT07434063 · ClinicalTrials.gov ↗ · Neutropenia
|
Observational | Recruiting | Hebei Medical University Fourth Hospital | China |
|
Mecapegfilgrastim Combined With Adebrelimab and Chemotherapy as Neoadjuvant Therapy in Resectable GC/GEJC
NCT06684158 · ClinicalTrials.gov ↗ · GC/GEJC
|
Phase 2 | Not yet open | The First Affiliated Hospital with Nanjing Medical University | China |
|
Mecapegfilgrastim for the Prevention of Dalpiciclib -Induced Neutropenia in Advanced Breast Cancer
NCT05463601 · ClinicalTrials.gov ↗ · Metastatic Breast Cancer
|
Phase 2 | Active, closed | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Fudan University | 1 |
| Affiliated Hospital of Nantong University | 1 |
| Hebei Medical University Fourth Hospital | 1 |
| Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 1 |
| The First Affiliated Hospital with Nanjing Medical University | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 5 | 3 |
A trial with sites in more than one country appears in each of those registers.
5 current trials in our China register name Mecapegfilgrastim as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 3 of the 5 trials are recruiting: 3 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Fudan University (1), Affiliated Hospital of Nantong University (1), Hebei Medical University Fourth Hospital (1) and Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (1), among 5 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Mecapegfilgrastim works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Mecapegfilgrastim works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Mecapegfilgrastim (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.